U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06931405) titled 'Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)' on April 09.
Brief Summary: This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Chronic Inducible Urticaria
Chronic Spontaneous Urticaria
Intervention:
DRUG: BLU-808
Oral administration
DRUG: Placebo
Oral administration
Recruitment Status: NOT_YET_RECRUITIN...